OncoMatch/Clinical Trials/NCT05901519
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Is NCT05901519 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Prednisone for hepatocellular carcinoma.
Treatment: Prednisone — Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Liver function
ALBI score equal to (-1.81) or higher (worse); CP score equal to 7 or higher (worse); decompensated liver disease (clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage) excluded
ALBI score equal to (-1.81) or higher (worse). CP score equal to 7 or higher (worse). Decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rogel Comprehensive Cancer Center · Ann Arbor, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify